CN113384601B - Composition for improving vaginal microecological balance - Google Patents
Composition for improving vaginal microecological balance Download PDFInfo
- Publication number
- CN113384601B CN113384601B CN202110815697.8A CN202110815697A CN113384601B CN 113384601 B CN113384601 B CN 113384601B CN 202110815697 A CN202110815697 A CN 202110815697A CN 113384601 B CN113384601 B CN 113384601B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- vaginal
- gel
- probiotic composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- 241000186660 Lactobacillus Species 0.000 claims abstract description 20
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 20
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 20
- 241000218492 Lactobacillus crispatus Species 0.000 claims abstract description 19
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 19
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 18
- 230000000529 probiotic effect Effects 0.000 claims abstract description 16
- 229940044950 vaginal gel Drugs 0.000 claims abstract description 10
- 239000000029 vaginal gel Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010046914 Vaginal infection Diseases 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 7
- 239000008272 agar Substances 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 241000222122 Candida albicans Species 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 201000008100 Vaginitis Diseases 0.000 claims description 6
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 6
- 229940095731 candida albicans Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 10
- 210000001215 vagina Anatomy 0.000 abstract description 7
- 239000000499 gel Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Abstract
The application provides a vaginal probiotic composition and a corresponding application and vaginal gel product, wherein the vaginal probiotic composition consists of lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus and staphylococcus epidermidis in specific proportions. The vaginal probiotic composition can effectively improve the adhesion of probiotics, inhibit the colonization of harmful bacteria and improve the microecological balance of the vagina.
Description
Technical Field
The application belongs to the fields of microorganisms and reproductive system disease treatment, and particularly provides a vaginal probiotic composition, a corresponding application and a vaginal gel product.
Background
The change of the flora and the unbalance of the quantity of the micro-ecological environment of the vagina can cause various vaginal diseases, such as colpitis, etc. At present, the clinical treatment means aiming at bacterial vaginal infection diseases mainly adopts antibiotic treatment, but the indiscriminate killing of vaginal microorganisms including probiotics/non-pathogenic bacteria by the antibiotic treatment can obviously change the microecological environment of the vagina and cause dysbacteriosis, thereby causing the problems of poor treatment effect, high recurrence rate and the like.
Therefore, transplantation of vaginal microorganisms for the treatment of diseases associated with dysregulated vaginal microecological environment is becoming more and more important. Compared with the flora in complete vaginal flora transplantation, the flora has high uncertainty factor and psychological and ethical problems of patients, and the microorganism/microorganism combination determined by the applied strain has more clinical operability. However, there is still a need to search for how to select suitable probiotics among many vaginal microorganisms, and how to better colonize the probiotics.
Disclosure of Invention
In order to solve the problems, the applicant conducts research on vaginal flora transplantation and vaginal probiotics preparation, and the applicant discovers that lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus and staphylococcus epidermidis have good vaginal colonization and harmful bacteria, in particular yeast inhibition effects in specific proportions. When the preparation is prepared into a gel preparation, the performance of the preparation can be further improved by adding a small amount of agar along with the prebiotics.
In one aspect, the present application provides a vaginal probiotic composition comprising lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus for improving vaginal microecological balance.
Further, lactobacillus rhamnosus, on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus was 5:3:3:2.
Further, the vaginal probiotic composition consists of lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus and staphylococcus epidermidis.
Further, lactobacillus rhamnosus, on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 5:3:3:2:0.5.
In another aspect, the present application provides the use of the above composition in the manufacture of a medicament for treating vaginitis.
In another aspect, the present application provides the use of the above composition in the preparation of a medicament for inhibiting candida albicans vaginal colonization.
In another aspect, the present application provides a vaginal gel characterized by comprising the vaginal probiotic composition described above.
Further, the gel component for vagina comprises 50 parts of sodium carboxymethyl cellulose, 20 parts of chitosan, 5 parts of tween-80, 2 parts of sodium chloride, 1 part of fructo-oligosaccharide, 1 part of malto-oligosaccharide and 3 parts of the vaginal probiotic composition.
Further, the vaginal gel composition further comprises 0.5 parts of agar.
Further, the vaginal probiotic composition is bacterial powder, wherein lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus and staphylococcus epidermidis are respectively: 2X 10 11 、1.2×10 11 、1.2×10 11 、8×10 10 、2×10 10 CFU/g。
The strain of the present application is not limited to the species described in the examples, and other commercially available species, the species mentioned in the article or patent, and the species to be screened/studied may be used in the present invention by suitable verification.
The composition can be used as a medicament or health-care product singly or in combination with other medicaments for treating colpitis, including but not limited to antibiotics, mucosa protectants and the like.
Detailed Description
Main experimental materials and methods:
lactobacillus rhamnosus: the Qingdaosen organism confirms that the original strain is CGMCC 1.120 through a supplier;
inert lactobacillus: the Qingdaosen organism, the original strain was identified as ATCC 55195 by the supplier;
lactobacillus gasseri: the Qingdaosen organism confirms that the original strain is CGMCC 1.3224 by a supplier;
lactobacillus crispatus: the Qingdaosen organism confirms that the original strain is CGMCC 1.2743 by a supplier;
staphylococcus epidermidis: the Qingdaosen organism, the original strain is confirmed to be CGMCC 1.1757 by the supplier.
Each strain was prepared to 1X 10 11 CFU/g-5×10 12 The bacteria powder with unequal CFU/g is provided, and the detected activity basically accords with the mark before use.
Other test bacteria and cells are provided for the Qingdaosen organism or the applicant can isolate and store themselves.
Fructo-oligosaccharides, malto-oligosaccharides, agar: jiangsu Qianchun biological technology Co.Ltd
Other reagents, culture mediums and detection kits are conventional domestic types meeting relevant standards.
Basic preparation method of gel
Weighing 50 parts of sodium carboxymethyl cellulose, 20 parts of chitosan, 5 parts of tween-80 and 2 parts of sodium chloride; mixing the weighed raw materials, adding 500 parts (according to 1 g/mL) of deionized water, and stirring for 1 hour; heating to 80 ℃ and stirring for 1 hour; stopping heating while continuing stirring, and adding the required amount of fructo-oligosaccharide, malto-oligosaccharide and/or agar when the mixture is cooled to 50 ℃; continuously stirring, adding the required amount of fungus powder when the temperature is cooled to 40 ℃, and uniformly stirring to obtain gel.
Adhesion experiments
Adding 1mL of each of a bacterial combination culture solution and a cell culture solution of 0.8 OD to Hela cells with 50% coverage on a slide; adding the mixture into a 24-well plate, and culturing for 2 hours at 37 ℃; sucking up the culture solution, and washing with PBS for 3 times; methanol was fixed and stained for observation.
And (3) field planting test:
inoculating Hela cells on a 24-hole plate, washing with PBS after the confluence rate is over 90%, and adding 1mL of cell culture medium for standby; 0.5mL or 0.5mL of the cell culture medium (control) and 1X 10 of the cell culture medium were added to the culture medium of the fungus combination cultured to 0.8. 0.8 OD 7 CFU candida albicans, or 1 x 10 8 CFU staphylococcus aureus co-cultured for 2 hours; PBS washing, adding 5% Triton X-100 200 microlitres for 10 minutes; adding 300 microliters of sterile water, blowing, sucking to dry, adding a corresponding bacterial culture medium, and culturing at a constant temperature of 37 ℃ for 24 hours; the inhibition of colonization relative to the control was calculated by colony count.
Rat vaginitis model test:
the model of vaginitis in rats (220.+ -.20 g) was entrusted to the preparation of the Wuhan Baphil organism using Staphylococcus aureus, streptococcus B hemolyticus and Candida albicans.
EXAMPLE 1 colonization effects of different seed compositions
According to the general knowledge in the art, vaginal probiotics mainly include lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus, lactobacillus salivarius, etc., and staphylococcus epidermidis is a gram-positive bacterium frequently detected in the vagina, and although it is generally considered harmless and is a normal type of microorganisms of the epidermis or vagina (conditional pathogenic bacteria, no exotoxin is produced, no harm is caused to the normal population of immunity), it is not used as a vaginal beneficial bacterium for transplantation. The auxiliary effect of staphylococcus epidermidis on other probiotics is found when the whole vaginal fungus is transplanted in earlier stage, and the auxiliary effect is a certain proportion
The partial correlation verification test is as follows
Combination 1: lactobacillus rhamnosus, calculated on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus is 5:3:3:2;
combination 2: lactobacillus rhamnosus, calculated on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 5:3:3:2:0.5;
combination 3: lactobacillus rhamnosus, calculated on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 7:3:3:5:0.5;
combination 4: lactobacillus rhamnosus, calculated on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 5:3:3:2:0.1;
combination 5: lactobacillus rhamnosus, calculated on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 5:5:5:2:0.5;
the above combinations were grown in BHI medium to an OD of about 0.8 for adhesion and colonization assays.
The results are shown in tables 1 and 2 below
TABLE 1 adhesion test results
| Fungus combination | Total number of bacillus per 100 Hela cells adhered (in the tested combination of species, bacillus could be considered as a probiotic) |
| Combination 1 | 7233 |
| Combination 2 | 9550 |
| Combination 3 | 9381 |
| Combination 4 | 7495 |
| Combination 5 | 7984 |
TABLE 2 results of field planting test
| Fungus combination | Staphylococcus aureus colonization resistance (compared to control meter) | Candida albicans planting resistance (compared with a control meter) |
| Combination 1 | 28.5 | 43.2 |
| Combination 2 | 32.1 | 56.9 |
| Combination 3 | 30.4 | 54.8 |
| Combination 4 | 27.8 | 45.7 |
| Combination 5 | 28.3 | 46.5 |
The results show that various bacteria combinations can realize the effects of cell adhesion and inhibition of the colonization of harmful bacteria, and the combination 2 and the combination 3 have data which are obviously superior to other combinations in the processes of adhesion and inhibition of the colonization of candida albicans, and by combining other data which are not shown, the addition of staphylococcus epidermidis in a specific proportion with lactobacillus inertia and lactobacillus gasseri can effectively promote the adhesion capability of the vaginal probiotics combination (presumably related to the interaction of bacteria), thereby improving the effect of inhibiting the colonization of the harmful bacteria.
Example 2 preparation of gel product and its therapeutic effect on rat vaginitis
According to the method and basic formulation described above, 1 part of fructo-oligosaccharide, 1 part of malto-oligosaccharide and 3 parts of the bacterial powder of combination 2 (Lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus, staphylococcus epidermidis 2X 10, respectively) essentially according to example 1 were used 11 、1.2×10 11 、1.2×10 11 、8×10 10 、2×10 10 CFU/g) was prepared as gel 1.
According to the method and basic formulation described above, 1 part of fructo-oligosaccharide, 1 part of malto-oligosaccharide, 0.5 part of agar and 3 parts of the bacterial powder of combination 2 (Lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus, staphylococcus epidermidis 2X 10, respectively) according to the basic embodiment 1 11 、1.2×10 11 、1.2×10 11 、8×10 10 、2×10 10 CFU/g) was prepared as gel 2.
Gel 3 was prepared using 1 part fructo-oligosaccharide, 1 part malto-oligosaccharide, 0.5 part agar according to the method and basic formulation described previously.
The above animal model 28 was equally divided into 4 groups, and gel 1, gel 2, gel 3 and metronidazole were administered (gel administered once daily, vaginal lavage and application around the vulva; metronidazole solution administered intragastrically 10 mg/day /). After 4 days of treatment, uterine tissue was sacrificed and IL-4 and TNF-alpha levels were detected by corresponding ELISA kits after homogenization.
TABLE 3 therapeutic effects of gels on rat vaginitis models
| Group of | IL-4（pg/mL） | TNF-α（pg/mL） |
| Gel 1 | 108±9 | 207±15 |
| Gel 2 | 137±12 | 173±21 |
| Gel 3 | 18±4 | 422±22 |
| Metronidazole | 115±14 | 185±19 |
As generally recognized in the art, the elevation of the anti-inflammatory cytokine IL-4 is beneficial for the treatment of inflammation and the relief of symptoms, whereas the pro-inflammatory cytokine TNF- α may represent the degree of inflammation. The data in table 3 shows that the gel formulations of the present application can be effective in improving the inflammatory state of the vagina.
Claims (7)
1. A vaginal probiotic composition for improving vaginal microecological balance, characterized in that it consists of lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus, staphylococcus epidermidis;
wherein lactobacillus rhamnosus, on CFU: inert lactobacillus: lactobacillus gasseri: lactobacillus crispatus: staphylococcus epidermidis is 5:3:3:2:0.5.
2. Use of a vaginal probiotic composition according to claim 1, in the preparation of a medicament for the treatment of vaginitis.
3. Use of a vaginal probiotic composition according to claim 1, for the preparation of a medicament for inhibiting candida albicans vaginal colonisation.
4. A vaginal gel comprising the vaginal probiotic composition according to claim 1.
5. The vaginal gel of claim 4 wherein the vaginal gel component comprises 50 parts sodium carboxymethyl cellulose, 20 parts chitosan, 5 parts tween-80, 2 parts sodium chloride, 1 part fructo-oligosaccharide, 1 part malto-oligosaccharide and 3 parts of the vaginal probiotic composition of claim 1.
6. The vaginal gel of claim 5 wherein said vaginal gel composition further comprises 0.5 parts agar.
7. The vaginal gel according to claim 5 or 6, wherein the vaginal probiotic composition according to claim 1 is a bacterial powder, wherein lactobacillus rhamnosus, lactobacillus inertia, lactobacillus gasseri, lactobacillus crispatus, staphylococcus epidermidis are respectively: 2X 10 11 、1.2×10 11 、1.2×10 11 、8×10 10 、2×10 10 CFU/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110815697.8A CN113384601B (en) | 2021-07-19 | 2021-07-19 | Composition for improving vaginal microecological balance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110815697.8A CN113384601B (en) | 2021-07-19 | 2021-07-19 | Composition for improving vaginal microecological balance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113384601A CN113384601A (en) | 2021-09-14 |
| CN113384601B true CN113384601B (en) | 2024-03-22 |
Family
ID=77626677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110815697.8A Active CN113384601B (en) | 2021-07-19 | 2021-07-19 | Composition for improving vaginal microecological balance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113384601B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201004A (en) * | 2019-06-27 | 2019-09-06 | 北京奥维森基因科技有限公司 | A kind of woman's probiotic composition, preparation method, its application and feminine care products |
| CN112342175A (en) * | 2021-01-09 | 2021-02-09 | 南京北极光生物科技有限公司 | Vaginal health probiotic composition and application thereof |
| CN112543804A (en) * | 2018-07-04 | 2021-03-23 | 科·汉森有限公司 | Aqueous topical compositions comprising live probiotic bacteria |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291696B2 (en) * | 2018-04-11 | 2022-04-05 | Shayne Morris | Pairing probiotics and prebiotics, methods for growth and use, separately and in combination |
-
2021
- 2021-07-19 CN CN202110815697.8A patent/CN113384601B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112543804A (en) * | 2018-07-04 | 2021-03-23 | 科·汉森有限公司 | Aqueous topical compositions comprising live probiotic bacteria |
| CN110201004A (en) * | 2019-06-27 | 2019-09-06 | 北京奥维森基因科技有限公司 | A kind of woman's probiotic composition, preparation method, its application and feminine care products |
| CN112342175A (en) * | 2021-01-09 | 2021-02-09 | 南京北极光生物科技有限公司 | Vaginal health probiotic composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113384601A (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7354274B2 (en) | Complex lactobacillus composition and its use in female vaginal health | |
| CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
| CN107299065B (en) | Lactobacillus plantarum and application thereof in preparation of vagina bacteriostatic drugs | |
| WO2015067141A1 (en) | Lactobacillus crispatus and application thereof | |
| CN108004188B (en) | Lactobacillus rhamnosus and application thereof in preparing vagina bacteriostatic medicine | |
| CN107267415B (en) | Lactobacillus reuteri and application thereof in preparing vagina bacteriostatic drug | |
| CN110540945B (en) | Lactobacillus jensenii and application thereof in preparing vaginal antibacterial drugs | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| CN107937324A (en) | One plant of Lactobacillus crispatus and its application | |
| CN113384601B (en) | Composition for improving vaginal microecological balance | |
| CN111567807A (en) | Rhamnose-containing lactobacillus composition for inhibiting inflammatory reaction and resisting vaginitis and application thereof | |
| CN111471623A (en) | Composition of three lactobacilli and application thereof | |
| KR20100079078A (en) | Pharmaceutical compositions including lactobacillus fermentum no. 1969 for treatment of vaginal infections | |
| CN112501051B (en) | Probiotic composite preparation and application thereof in vaginal flora regulation and HPV resistance | |
| CN114561330A (en) | Composite microbial inoculum for preventing and treating genital tract infection | |
| CN111281896B (en) | Composite microbial inoculum for adjusting micro-ecological balance of gynecology | |
| Tareq et al. | An application of Bacteriocin-Producing Vaginal Lactobacillus Crispatus IS30 in A Gel Formula Against Some Vaginal Pathogens | |
| CN117511826B (en) | Lactobacillus mucilaginosus and application thereof | |
| CN116769676B (en) | Lactobacillus crispatus and application thereof | |
| CN117535206B (en) | Lactobacillus salivarius and application thereof | |
| CN117535208B (en) | Lactobacillus crispatus and application thereof in female genital tract health | |
| CN116948922B (en) | Lactobacillus gasseri VB247 and application thereof | |
| CN116622579A (en) | Lactobacillus plantarum and application thereof | |
| CN117535209B (en) | Lactobacillus brevis and application thereof in female genital tract health | |
| Babenko et al. | Prophylactic effect of lactobacilli and bifidobacteria probiotic strains on experimental bacterial vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |